{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-007256","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.431405+00:00","generated_at":"2026-05-16T20:18:03.044140+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arbutus Q3 net loss $7.7M ($0.04/sh); cash $93.7M; imdusiran data positive","bullets":["Net loss of $7.7M ($0.04 per share) vs $19.7M ($0.10) in Q3 2024.","Revenue fell to $0.5M from $1.3M due to lower Alnylam ONPATTRO royalties.","Cash, equivalents and marketable securities $93.7M at Sep 30, 2025, down from $122.6M at Dec 31, 2024.","Moderna US trial set for March 2026; Pfizer-BioNTech claim construction ruling favorable in Sep 2025.","Imdusiran: 46% of Phase 2a patients discontinued all treatment; 94% of long-term follow-up off treatment up to 2+ years."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-007256","json":"https://secwatch.observer/filing/0001171843-25-007256.json","markdown":"https://secwatch.observer/filing/0001171843-25-007256.md","text":"https://secwatch.observer/filing/0001171843-25-007256.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325007256/0001171843-25-007256-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325007256/f8k_111325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:18:03.044140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}